Ingredient and regulatory evidence guide · Updated August 17, 2026
Does GrandeLASH-MD contain a prostaglandin analogue?
Yes. As reviewed August 17, 2026, Grande Cosmetics' current U.S. GrandeLASH-MD ingredient information identifies isopropyl cloprostenate as a prostaglandin analogue. Under an ingredient-class definition, GrandeLASH-MD is therefore not prostaglandin-free.
This conclusion is based on Grande's own current ingredient disclosure, not on inference from a trademarked complex name.
That ingredient fact does not mean every prescription-bimatoprost adverse effect occurs at the same rate with GrandeLASH-MD. It does mean shoppers who want to avoid the prostaglandin-analogue class should not categorize the current U.S. GrandeLASH-MD formula as prostaglandin-free.
What is isopropyl cloprostenate?
Isopropyl cloprostenate, often shortened to IPCP, is a synthetic prostaglandin analogue used in some cosmetic lash serums. Grande describes it as a prostaglandin analogue and hair-conditioning cosmetic ingredient. It is distinct from bimatoprost, the active drug in prescription LATISSE, and this page does not treat the two ingredients as identical products or assign bimatoprost event rates to GrandeLASH-MD.
To learn the chemical-name screening method, read Plume's isopropyl cloprostenate guide and the broader prostaglandin-free ingredient reference.
How regulators classify this ingredient class
| Source | What the source says | What it means for this page |
|---|---|---|
| Grande Cosmetics | The current brand page calls isopropyl cloprostenate a prostaglandin analogue and lists it in GrandeLASH-MD. | The current U.S. formula is not prostaglandin-free under an ingredient-class definition. |
| Health Canada | In December 2019, Health Canada added prostaglandins, their salts, derivatives, and analogues, including isopropyl cloprostenate, to the Cosmetic Ingredient Hotlist's prohibited table because the class has a therapeutic function and appears on the Prescription Drug List. | IPCP is not permitted as an intentionally added ingredient in a cosmetic sold in Canada. |
| EU Scientific Committee on Consumer Safety | Final Opinion SCCS/1680/25 concluded that IPCP, MDN, and DDDE cannot be considered safe for cosmetic products intended to promote eyelash or eyebrow growth. | The opinion addresses the cosmetic ingredient class; it does not provide a GrandeLASH-specific incidence rate. |
What happened in the Grande Cosmetics class settlement?
In Nixon v. Grande Cosmetics, LLC, U.S. District Court for the District of New Jersey, No. 1:22-cv-06639, plaintiffs alleged inadequate disclosures concerning isopropyl cloprostenate and potential adverse reactions in certain enhancement serums. Grande denied the allegations, denied liability, and maintained that the products were cosmetics.
The settlement agreement created a $6.25 million cash settlement fund and required specified label, instruction, warning, ingredient-declaration, and website changes. The court granted final approval on July 18, 2024. The agreement expressly states that the settlement was not an admission of liability or wrongdoing.
What is known about side effects?
Prescription bimatoprost labels and ophthalmology literature document eye-area adverse effects associated with prostaglandin drugs, including eyelid pigmentation and periorbital changes. Those sources establish why the class deserves careful review, but they do not establish that GrandeLASH-MD causes every listed effect, that the incidence is the same, or that every effect is permanent.
Grande states that it completed a toxicological risk assessment and considers GrandeLASH-MD safe when used as intended. Its current product information also instructs users to apply sparingly, avoid the eye, stop use if redness or irritation occurs, and seek medical attention if symptoms persist. The settlement materials include expanded warnings not to use the product while pregnant or nursing, under age 18, on damaged or irritated skin, or in specified eye and medical circumstances.
Consumers should weigh the brand's finished-product safety position alongside the ingredient classification, current directions and warnings, Health Canada's prohibition for cosmetics, and the SCCS final opinion.
How to spot prostaglandin analogues on a lash-serum label
Check the current complete INCI instead of relying only on front-label terms such as “peptide complex.” Names to recognize include:
- Isopropyl cloprostenate (IPCP)
- Dechloro dihydroxy difluoro ethylcloprostenolamide (DDDE), also called ethyl tafluprostamide
- Methylamido-dihydro-noralfaprostal (MDN)
- Bimatoprost, the active drug in LATISSE
Formulas can change by region and over time, so the package in hand is the final check.
Frequently asked questions
Is GrandeLASH-MD prostaglandin-free?
No. Grande's current U.S. ingredient information identifies isopropyl cloprostenate as a prostaglandin analogue.
Which prostaglandin analogue is in GrandeLASH-MD?
The current U.S. formula lists isopropyl cloprostenate, often abbreviated IPCP.
Is isopropyl cloprostenate the same as bimatoprost?
No. They are distinct compounds within the broader prostaglandin-analogue category. Bimatoprost is the active prescription drug in LATISSE; Grande describes IPCP as a cosmetic hair-conditioning ingredient.
Can GrandeLASH-MD be sold as a cosmetic in Canada?
Health Canada's current prohibited cosmetic-ingredient table includes prostaglandins, their derivatives and analogues and specifically names isopropyl cloprostenate among related compounds.
Was the Grande Cosmetics settlement an admission of wrongdoing?
No. The settlement agreement states that Grande denied the allegations and liability and that the settlement was not an admission of wrongdoing.
Primary sources
- Grande Cosmetics: GrandeLASH-MD key ingredients and IPCP classification
- Grande Cosmetics: current GrandeLASH-MD product page, INCI, warnings, and directions
- Health Canada Cosmetic Ingredient Hotlist: prostaglandins, derivatives, and analogues
- SCCS Final Opinion SCCS/1680/25, adopted February 2, 2026
- Nixon v. Grande Cosmetics final approval order, July 18, 2024
- Nixon v. Grande Cosmetics settlement agreement, including allegations, denial, fund, disclosures, and no-admission clause
Related: How to grow eyelashes with realistic timelines · How to verify a prostaglandin-free formula
This page provides ingredient and regulatory education, not medical or legal advice.